It has also been shown to sensitise colorectal cancer (CRC) cells to 5-FU treatment via p-glycoprotein inhibition and a reduction in NF-κB acetylation/NF-κB protein ratio, suppressing NF-κB Activation [57]. The gene discussed is NFKB1; the disease is colorectal carcinoma.